EASD24 – Talk Bio

Actionable Insights Powered by AI

Novo Nordisk’s Saxenda Demonstrates Significant Weight Loss in Children Aged 6-12 in Phase III Trial

7 months ago talkbio0Tagged EASD24, Nordisk, Obesity, Pediatric brand name, Phase 3 Clinical Trials, Saxenda

Saxenda, Novo Nordisk, pediatric obesity, weight loss, Phase III trial, EASD24

EASD24: Lilly’s Weekly Insulin Efsitora Demonstrates Efficacy but Raises Hypoglycemia Concerns

7 months ago talkbio0Tagged Diabetes, Diabetes Mellitus, Non-Insulin-Dependent, EASD24, efsitora, Eli, Eli Lilly, Hypoglycemia, Insulin, insulin therapy, Weekly

Eli Lilly, EASD24, Weekly Insulin, Efsitora, Type 1 Diabetes, Type 2 Diabetes, Hypoglycemia, Insulin Therapy